Rheumatoid Arthritis Whole Blood
Fresh whole blood from IRB-consented donors with clinically confirmed rheumatoid arthritis, shipped same day. Whole blood retains neutrophils and granulocytes that PBMC isolation removes, making it suited to ACPA and citrullination research, whole-blood transcriptomics, ex vivo stimulation assays and HLA genotyping. Donors can be stratified by anti-CCP and RF serostatus, disease activity, erosive status and DMARD, biologic or JAK inhibitor treatment, with matched healthy controls available.
Rheumatoid Arthritis Whole Blood for Autoimmune and Rheumatology Research
Rheumatoid arthritis (RA) is a systemic autoimmune disease in which anti-citrullinated protein antibodies (ACPA, measured clinically as anti-CCP) and rheumatoid factor drive persistent synovial inflammation, pannus formation and progressive joint erosion. Sanguine collects fresh whole blood from IRB-consented donors with a clinically confirmed RA diagnosis for rheumatology, autoimmunity and immunology research.
Why Whole Blood for Rheumatoid Arthritis Research
- Whole blood is the only routine peripheral specimen that retains every leukocyte lineage. Neutrophils and low-density granulocytes are lost during density-gradient PBMC isolation, yet neutrophils are central to RA: they are the dominant cell in synovial fluid and they externalise citrullinated autoantigen through extracellular trap formation.
- Because whole blood preserves the native leukocyte composition, it supports unbiased transcriptomic profiling in which granulocyte and platelet signatures are preserved rather than removed by upstream cell separation.
- ACPA and rheumatoid factor can be detected years before clinical synovitis, and the ACPA-positive and ACPA-negative subsets differ in genetics, including the HLA-DRB1 shared epitope association. Whole blood yields matched genomic DNA for HLA and risk-allele genotyping alongside the same donor’s serology.
- Whole blood supports ex vivo stimulation in a physiological matrix, so TNF, IL-6 and JAK/STAT pathway responses can be measured with the plasma proteins, complement and erythrocytes still present.
- RA is treated across mechanistically distinct classes including methotrexate, TNF inhibitors, IL-6 receptor blockade, T-cell costimulation blockade, B-cell depletion and JAK inhibitors. Whole blood from donors on each class enables pharmacodynamic and target-engagement assay development.
- Fresh whole blood also allows same-day functional assays such as flow cytometry immunophenotyping, whole-blood cytokine release, platelet studies and viability-sensitive workflows that cryopreserved fractions cannot support.
Donor Stratification Available
- Serostatus: anti-CCP/ACPA positive or negative, and rheumatoid factor positive or negative
- Disease activity where documented, including DAS28, CDAI, ESR and CRP, and active disease versus remission
- Disease duration and erosive versus non-erosive radiographic status
- Treatment status: treatment-naive, conventional synthetic DMARD, TNF inhibitor, IL-6 receptor inhibitor, T-cell costimulation blockade, B-cell depletion, or JAK inhibitor
- Extra-articular and comorbid features where documented, including interstitial lung disease, nodules and secondary Sjogren’s syndrome
- Matched healthy controls available, and other inflammatory arthritis donors such as psoriatic arthritis for comparison
Product Features
- Fresh whole blood from clinically diagnosed RA donors
- Custom anticoagulants and collection tubes available, including EDTA, sodium heparin, ACD and RNA-stabilising tubes
- Same-day collection and shipment
- Research Use Only (RUO)
- Draw volumes specified per collection and reported per lot
De-identified Donor Data
- Physician-confirmed diagnosis, including anti-CCP and RF status where available
- Demographics: age, sex assigned at birth, ethnicity
- Relevant medical and treatment history
- Additional RA-specific clinical detail available on request
Applications
- Anti-CCP/ACPA and rheumatoid factor autoantibody research
- Whole-blood immunophenotyping including granulocyte and low-density neutrophil populations
- Whole-blood transcriptomics, gene expression signatures and epigenetic profiling
- Ex vivo stimulation and cytokine release assays in a physiological matrix
- Pharmacodynamic and target-engagement assays for DMARD, biologic and JAK inhibitor programmes
- Genomic DNA extraction for HLA-DRB1 and risk-allele genotyping
- Neutrophil extracellular trap and citrullination research
- Source material for downstream PBMC, granulocyte, plasma and serum preparation
Other Rheumatoid Arthritis Specimen Types
- Rheumatoid Arthritis Serum
- Rheumatoid Arthritis Plasma
- Rheumatoid Arthritis PBMC
- Rheumatoid Arthritis Leukopak
- Rheumatoid Arthritis Bulk Plasma
- Rheumatoid Arthritis Synovial Fluid
- Rheumatoid Arthritis CD19+ B Cells
- Rheumatoid Arthritis CD4+ T Cells
Compliance and Quality Assurance
- IRB-approved protocols and electronic informed consent
- HIPAA-compliant donor data handling
- Documentation support available for regulatory review
Ordering & Customization
RA whole blood is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. Email us as well for international orders or documentation requirements. To browse other disease states in this specimen type, visit our human whole blood page.
Whole Blood
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Whole Blood cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.